TRIOAR
Latest round
- Series B
Last raised
- Aug 2025
Total raised
- $27M
Investors
- 15
About TRIOAR
Based in Daejeon, South Korea, and founded in 2021, TRIOAR is a new drug development company that develops a platform technology that improves the limitations of antibody therapeutics, antibody-drug conjugates, or ADCs, and seeks to develop next-generation drugs. As of February 2022, Mr. Seong-ho Woo is the CEO of TRIOAR. The product pipeline of TRIOAR includes A-01, P-01, T-01, T-02, T-03, TA-01, TA-02, I-01, E-01, and B-02 for indications, such as breast cancer, solid cancer, breast cancer, TNBC, gastric cancer, solid cancer blood cancer, PDAC, and NSCLC. In addition, the company provides a platform technology that can be applied to multiple targets in multiple functional areas.
Who invested in TRIOAR
15 investors across 3 rounds
See all investors in TRIOAR
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about TRIOAR
Who invested in TRIOAR?
TRIOAR has 15 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TRIOAR raised?
TRIOAR has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did TRIOAR last raise money?
TRIOAR's most recent round on record is a Series B, in Aug 2025.
What does TRIOAR do?
Based in Daejeon, South Korea, and founded in 2021, TRIOAR is a new drug development company that develops a platform technology that improves the limitations of antibody therapeutics, antibody-drug conjugates, or ADCs, and seeks to develop next-generation drugs.
Where is TRIOAR headquartered?
TRIOAR is headquartered in Daejeon, South Korea.
Which VCs invest in companies like TRIOAR?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at TRIOAR's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like TRIOAR? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.